A retrospective observational study of the occurrence of pneumothorax and/or pneumomediastinum in patients with interstitial lung diseases treated with antifibrotic drugs

A retrospective observational study of the occurrence of pneumothorax and/or pneumomediastinum in patients with interstitial lung diseases treated with antifibrotic drugs - Pneumothorax and/or pneumomediastinum in patients with interstitial lung diseases treated with antifibrotic drugs

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051398

Enrollment

Registered

2023-06-21

Start date

2023-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

interstitial lung disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with interstitial lung diseases who received the antifibrotic drugs, nintedanib or pirfenidone, at Kochi University Hospital from December 1, 2008 to September 30, 2022

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Incidence of pneumothorax and/or pneumomediastinum in patients with interstitial lung diseases treated with antifibrotic drugs	—

Secondary

Measure	Time frame
Rate of refractory pneumothorax and/or pneumomediastinum in patients with interstitial lung diseases treated with antifibrotic drugs	—

Countries

Japan

Contacts

Public ContactHiroshi Ohnishi

Kochi Medical School, Kochi University Department of Respiratory Medicine and Allergology

honi@kochi-u.ac.jp088-880-2345

Outcome results